News for Verastem, Inc. (0LOV.L)

PR NewswireVANCOUVER, BC, July 23, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, July 23, 2025 /PRNewswire/

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an analysis of VSTM stock now.

Verastem (VSTM) has disclosed findings from its Phase 2 RAMP 201 clinical trial, which is now available online in the Journal of Clinical Oncology. The study re

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term growth. Learn why VSTM stock is a buy.

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASD...

Verastem (VSTM) Oncology has shared encouraging results from the Phase 1/2 trial of GFH375, focusing on dose escalation for treating pancreatic ductal adenocarc

In the opening quarter of 2025, Verastem (VSTM) Oncology has achieved significant milestones in its pipeline initiatives. The company has exercised an early opt

B. Riley has elevated its price target for Verastem (VSTM) from $12 to $13, maintaining a Buy rating on the stock. The upward revision comes as Verastem announc

On May 9, 2025, HC Wainwright & Co. analyst Sean Lee maintained a "Buy" rating on Verastem (VSTM). The financial services firm raised its price target for VSTM

RBC Capital's analyst has elevated Verastem's (VSTM) price target from $14 to $16 while maintaining an Outperform rating on its stock. This upgrade reflects Ver

Jefferies analyst Kelly Shi has boosted the price target for Verastem (VSTM) to $19 from the previous $15 while maintaining a Buy rating on the company's stock.

Verastem (VSTM) has announced a conference call slated for May 1 at 11 a.m., featuring its President & CEO, Paterson, along with Chief Scientific Officer, Pacht

Overview of BlackRock's Recent Transaction On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a strategic acquisition by adding 77,131 shares of Ve

Key Highlights: Verastem Oncology's new drug targets the KRAS G12D mutation with FDA approval. Analysts predict a significant upside potential for Verast

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

Jefferies initiates coverage on Verastem (VSTM) with a

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's...

Shares of Harrow, Inc. HROW rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial resul...